Concepedia

A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva®, OSI-774) in patients with advanced solid tumors of epithelial origin

Malcolm Ranson, Heather Shaw, Jürgen Wolf, Marta Hamilton, S P McCarthy, Emma Dean, Alison Reid, Ian Judson

Cancer Chemotherapy and Pharmacology · 2009 · 36 citations · 5 references

DOIFull text

Open access

Concepts

References

5

Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

Manuel Hidalgo, Lillian L. Siu, John Nemunaitis et al. · Journal of Clinical Oncology · 2001 · 1K citations

, , +15

BindingDB Entry 50022536: Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase.

PubMed · 2025 · 844 citations · Full text

, , +17

Effects of Smoking on the Pharmacokinetics of Erlotinib

Marta Hamilton, Julie Wolf, Jason Rusk et al. · Clinical Cancer Research · 2006 · 311 citations · Full text

, , +10

Overcoming CYP1A1/1A2 Mediated Induction of Metabolism by Escalating Erlotinib Dose in Current Smokers

Andrew Hughes, Mary O’Brien, W. Jeffrey Petty et al. · Journal of Clinical Oncology · 2009 · 142 citations · Full text

, , +13

Evaluation of the Absolute Oral Bioavailability and Bioequivalence of Erlotinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in a Randomized, Crossover Study in Healthy Subjects

Paul Frohna, Jianfeng Lu, Steve Eppler et al. · The Journal of Clinical Pharmacology · 2006 · 111 citations

, , +15